(NASDAQ: MYGN) Myriad Genetics's forecast annual revenue growth rate of -3.05% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 6.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.32%.
Myriad Genetics's revenue in 2026 is $803,600,000.On average, 11 Wall Street analysts forecast MYGN's revenue for 2026 to be $76,950,704,075, with the lowest MYGN revenue forecast at $73,755,535,726, and the highest MYGN revenue forecast at $79,567,461,582. On average, 11 Wall Street analysts forecast MYGN's revenue for 2027 to be $71,025,590,028, with the lowest MYGN revenue forecast at $61,280,854,137, and the highest MYGN revenue forecast at $82,212,995,748.
In 2028, MYGN is forecast to generate $71,376,665,266 in revenue, with the lowest revenue forecast at $64,693,765,870 and the highest revenue forecast at $84,874,836,687.